BioCryst (BCRX) Q2 Revenue Jumps 50%
BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotechnology company specializing in oral treatments for rare diseases, released its second quarter earnings on August 4, 2025, reporting its strongest quarterly results to date. The headline news was the company’s first significant profit on a generally accepted accounting principles (GAAP) basis, with GAAP revenue and non-GAAP earnings both outstripping Wall Street expectations. GAAP revenue was $163.4 million, 9.1% higher than the analyst consensus of $149.8 million, and non-GAAP earnings per share climbed to $0.15 versus the $0.007 estimate. The quarter marked a shift from prior-year losses to profit, as BioCryst reported GAAP net income of $5.1 million compared to a GAAP net loss of $12.7 million in Q2 2024, underscoring surging demand for ORLADEYO, which achieved $156.8 million in net revenue, up 45% year-over-year, and set a positive tone for the year ahead.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
BioCryst Pharmaceuticals is known for its focus on rare disease therapies and relies on a unique structure-guided approach to drug design. Its key product is ORLADEYO, an oral therapy for hereditary angioedema (HAE), a rare disorder causing severe and unpredictable swelling episodes. The company develops and commercializes treatments aimed at patient populations with few existing options, targeting both U.S. and international markets.
Source Fool.com
